Physician profile
West Ky Abrams
NPI 1982703385
$3,058.32
in general payments reported to CMS, 2019-2025
34 companies · $664 in 2025
The $664 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $161 · 2021: $236 · 2022: $254 · 2023: $414 · 2024: $358 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $558.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.73 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $310.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $272.67 | 2019-2025 | Synthroid, Ubrelvy |
| Amarin Pharma, INC. | $197.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.62 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $119.03 | 2019-2021 | |
| Antares Pharma, INC. | $90.37 | 2024-2025 | Xyosted |
| Corcept Therapeutics | $82.38 | 2025 | Korlym |
| Halozyme INC | $75.41 | 2023 | |
| Astellas Pharma US INC | $69.61 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $68.07 | 2019-2025 | Aptima |
| Glaxosmithkline, LLC. | $63.15 | 2023-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $60.73 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $58.78 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.68 | 2019 | |
| Allergan, INC. | $49.83 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $39.32 | 2019 | |
| Verity Pharmaceuticals INC. | $33.99 | 2025 | Tlando |
| Abbott Laboratories | $33.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $32.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.62 | 2019 | |
| Amneal Pharmaceuticals LLC | $31.80 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $30.92 | 2020-2021 | |
| Alkermes, INC. | $29.80 | 2025 | Vivitrol |
| Alnylam Pharmaceuticals INC. | $29.56 | 2025 | Givlaari |
| Xeris Pharmaceuticals, INC. | $24.18 | 2025 | Recorlev |
| Zyla Life Sciences, INC. | $20.33 | 2019 | |
| Amgen INC. | $19.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.82 | 2024 | |
| Tolmar, INC. | $15.28 | 2023 | |
| Ibsa Pharma INC. | $14.39 | 2020 | |
| Phadia US INC. | $13.90 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw West Ky Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.